Advanced breast cancer patients living longer thanks to improvements in treatment and careAdvanced breast cancer patients living longer thanks to improvements in treatment and care
People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the average survival time for patients diagnosed in 2011, according to a major study of patient data in the US presented at the Advanced Breast Cancer Eighth International Consensus Conference (ABC8).
Global survey highlights challenges faced by young women with advanced breast cancerGlobal survey highlights challenges faced by young women with advanced breast cancer
Nearly half of all women aged younger than 40 who live with advanced breast cancer have children under the age of 18, according to the first global survey to investigate the challenges these women face. Results from the survey were presented to the Advanced Breast Cancer Eighth International Consensus Conference (ABC8).
Global Decade Report reveals breakthroughs in advanced breast cancer but exposes a widening global equity gapGlobal Decade Report reveals breakthroughs in advanced breast cancer but exposes a widening global equity gap
The ABC Global Alliance today launched the Advanced Breast Cancer (ABC) Global Decade Report 2015–2025—a global assessment revealing a decade of remarkable scientific progress that has transformed ABC care for some patients in some countries, while many others around the world have yet to benefit.
Existing drug could reduce breast cancer risk in pre-menopausal womenExisting drug could reduce breast cancer risk in pre-menopausal women
A University of Manchester study reveals a drug approved for use in other conditions could be repurposed as a preventive breast cancer treatment in women before menopause.
Macrophage ‘bodyguard’ disruptors may help overcome hormone-resistant breast cancerMacrophage ‘bodyguard’ disruptors may help overcome hormone-resistant breast cancer
In preclinical studies, researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, have tested a new combination therapy for hormone-resistant, estrogen receptor-positive (ER+) breast cancer and were able to shrink tumors, reduce the number of cancer stem cells and reprogram the immune environment to be less supportive of cancer growth.
GLP-1 Agonists Tied to Lower Risk of Death in Dialysis PatientsGLP-1 Agonists Tied to Lower Risk of Death in Dialysis Patients
(MedPage Today) — Use of GLP-1 receptor agonists was associated with a lower risk of mortality for dialysis patients with type 2 diabetes, according to a retrospective cohort study of Medicare enrollees. Among over 151,000 patients, use of GLP… (MedPage Today) — Use of GLP-1 receptor agonists was associated with a lower risk of Read More
Mandatory nutrient warning labels could prevent 100,000+ obesity-related deathsMandatory nutrient warning labels could prevent 100,000+ obesity-related deaths
Researchers from the University of Liverpool have found that making front-of-pack nutrition labeling mandatory could significantly reduce obesity rates and save thousands of lives across England.
Voting and Early Death; White House’s $149 Wegovy Plan; An $800,000 Placebo?Voting and Early Death; White House’s $149 Wegovy Plan; An $800,000 Placebo?
(MedPage Today) — Note that some links may require registration or subscription. A Finnish study found that voters had a lower risk for all-cause death over 21 years of follow-up compared with non-voters. (Journal of Epidemiology & Community… (MedPage Today) — Note that some links may require registration or subscription. A Finnish study found Read More
White House nears deal to lower prices for weight loss drugs Wegovy and ZepboundWhite House nears deal to lower prices for weight loss drugs Wegovy and Zepbound
The Trump administration is preparing to announce a deal this week with Eli Lilly and Novo Nordisk to lower the price of their weight loss drugs, a person familiar with the plan said. The Trump administration is preparing to announce a deal this week with Eli Lilly and Novo Nordisk to lower the price of Read More
World’s Best-Selling Med; Cost-Effectiveness of GLP-1 Drugs; TED Drug Heads to FDAWorld’s Best-Selling Med; Cost-Effectiveness of GLP-1 Drugs; TED Drug Heads to FDA
(MedPage Today) — The GLP-1 receptor agonist tirzepatide (Zepbound, Mounjaro) surpassed the cancer immunotherapy drug pembrolizumab (Keytruda) as the world’s best-selling medicine. (STAT) An Institute for Clinical and Economic Review report concluded… (MedPage Today) — The GLP-1 receptor agonist tirzepatide (Zepbound, Mounjaro) surpassed the cancer immunotherapy drug pembrolizumab (Keytruda) as the world’s best-selling medicine. Read More